Hosted on MSN

Eli Lilly Stock (LLY) Rises as Competitor Novo Nordisk Cuts Guidance

Eli Lilly’s stock (LLY) is trending higher on Nov. 5 after archrival Novo Nordisk (NVO) lowered its growth outlook ...

Novo Nordisk trims outlook as obesity drug maker loses ground to Eli Lilly

COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk trimmed its full-year forecasts on Wednesday as sales growth of its ...
Fierce Pharma

Lilly, Novo Nordisk in pricing, coverage talks with Trump administration on obesity meds: Endpoints

The Trump administration has spent much of this year working to coerce drugmakers into lowering their prices in the U.S. | ...

Novo Nordisk latest outlook trim shows “quick momentum loss”

Novo Nordisk has cut its outlook for 2025 as lower expectations for glucagon-like peptide-1 receptor agonists (GLP-1RA) continue to hit the drugmaker. Net profit for Q3 came in at Dkr20bn ($3.1bn), ...
Devdiscourse

Novo Nordisk Battles Market Shifts Amid Obesity Drug Rivalry

Novo Nordisk lowered its forecasts due to slowing sales of its obesity drugs amid competition from Eli Lilly and generic ...

Pfizer files second lawsuit against Novo Nordisk, Metsera in bidding war over obesity biotech

The suit escalates a battle between Pfizer and Novo Nordisk over Metsera, whose obesity pipeline could yield new competitors ...